186 related articles for article (PubMed ID: 29723078)
1. Evaluation of the losartan solubility in the biowaiver context by shake-flask method and intrinsic dissolution.
Souza JB; Souza J; Castro LML; Siqueira MF; Savedra RML; Silva-Barcellos NM
Pharm Dev Technol; 2019 Mar; 24(3):283-292. PubMed ID: 29723078
[TBL] [Abstract][Full Text] [Related]
2. The Evaluation of Valsartan Biopharmaceutics Properties.
de Castro LML; de Souza J; Caldeira TG; de Carvalho Mapa B; Soares AFM; Pegorelli BG; Della Croce CC; Barcellos NMS
Curr Drug Res Rev; 2020; 12(1):52-62. PubMed ID: 31820707
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
4. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
5. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
Strauch S; Jantratid E; Dressman JB
J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
[TBL] [Abstract][Full Text] [Related]
6. Folic acid: a biopharmaceutical evaluation.
Bellavinha KR; Silva-Barcellos NM; Souza JB; Leite JC; Souza Jd
Pharm Dev Technol; 2015; 20(6):730-7. PubMed ID: 24867254
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
Charoo NA; Cristofoletti R; Dressman JB
J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
[TBL] [Abstract][Full Text] [Related]
8. Chemometrics-assisted spectrophotometric green method for correcting interferences in biowaiver studies: Application to assay and dissolution profiling study of donepezil hydrochloride tablets.
Korany MA; Mahgoub H; Haggag RS; Ragab MAA; Elmallah OA
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jun; 199():328-339. PubMed ID: 29627618
[TBL] [Abstract][Full Text] [Related]
9. Design, Preparation and evaluation of various parameters of controlled release matrices of losartan potassium using polymers combination.
Khan KA; Khan GM; Shah KU; Niazi ZR; Khan H; Ahmad A; -Ur-Rehman F; Shah PA; Ullah A; Tahir M; Jan SU
Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2231-2237. PubMed ID: 33832895
[TBL] [Abstract][Full Text] [Related]
10. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
11. Proof-of-concept for a miniaturized shake-flask biopharmaceutical solubility determination by sonic mixing.
Veseli A; Kristl A; Akelj S
Pharmazie; 2020 Dec; 75(12):626-631. PubMed ID: 33303054
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
13. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
Lin Z; Zhou D; Hoag S; Qiu Y
AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
[TBL] [Abstract][Full Text] [Related]
14. Commonality between BCS and TCS.
Shah VP; Rădulescu FŞ; Miron DS; Yacobi A
Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets.
Drašković M; Medarević D; Aleksić I; Parojčić J
Drug Dev Ind Pharm; 2017 May; 43(5):723-731. PubMed ID: 27494420
[TBL] [Abstract][Full Text] [Related]
16. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug.
Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F
Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872
[TBL] [Abstract][Full Text] [Related]
17. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
[TBL] [Abstract][Full Text] [Related]
18. In vitro availability of atorvastatin in presence of losartan.
Arayne MS; Sultana N; Haroon U; Qureshi F; Ali SA
Pak J Pharm Sci; 2006 Apr; 19(2):134-41. PubMed ID: 16751125
[TBL] [Abstract][Full Text] [Related]
19. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
Okumu A; DiMaso M; Löbenberg R
Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
[TBL] [Abstract][Full Text] [Related]
20. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
Chella N; Tadikonda R
Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
